Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Research ArticleADULT BRAIN

Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas

D. Daniels, D. Guez, D. Last, C. Hoffmann, D. Nass, A. Talianski, G. Tsarfaty, S. Salomon, A.A. Kanner, D.T. Blumenthal, F. Bokstein, S. Harnof, D. Yekutieli, S. Zamir, Z.R. Cohen, L. Zach and Y. Mardor
American Journal of Neuroradiology July 2016, DOI: https://doi.org/10.3174/ajnr.A4866
D. Daniels
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Daniels
D. Guez
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Guez
D. Last
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Last
C. Hoffmann
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Hoffmann
D. Nass
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Nass
A. Talianski
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Talianski
G. Tsarfaty
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for G. Tsarfaty
S. Salomon
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Salomon
A.A. Kanner
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.A. Kanner
D.T. Blumenthal
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D.T. Blumenthal
F. Bokstein
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F. Bokstein
S. Harnof
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Harnof
D. Yekutieli
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D. Yekutieli
S. Zamir
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. Zamir
Z.R. Cohen
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Z.R. Cohen
L. Zach
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for L. Zach
Y. Mardor
From the Oncology Institute (L.Z., A.T.), Advanced Technology Center (D.G., D.L., D.D., S.S., Y.M.), Department of Neurosurgery (Z.R.C., S.H.), Radiology Institute (C.H., G.T.), and Pathology Institute (D.N.), Sheba Medical Center, Ramat-Gan, Israel; Sackler Faculty of Medicine (L.Z., D.D., C.H., G.T., Z.R.C., Y.M., S.H.) and School of Mathematical Sciences (D.Y., S.Z.), Tel-Aviv University, Tel-Aviv, Israel; and Neuro- Oncology Service (D.T.B., F.B.) and Stereotactic Radiosurgery Unit (A.A.K.), Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Y. Mardor
  • Article
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: The interpretation of the radiologic response of bevacizumab-treated patients with recurrent high-grade gliomas represents a unique challenge. Delayed-contrast MR imaging was recently introduced for calculating treatment-response-assessment maps in patients with brain tumors, providing clear separation between active tumor and treatment effects. We studied the application of standard and delayed-contrast MR imaging for assessing and predicting the response to bevacizumab.

MATERIALS AND METHODS: Twenty-four patients with recurrent high-grade gliomas were scanned before and during bevacizumab treatment by standard and delayed-contrast MR imaging. The mean change in lesion volumes of responders (overall survival, ≥1 year) and nonresponders (overall survival, <1 year) was studied. The lesion volumes at baseline and the changes in lesion volumes 1 month after treatment initiation, calculated from standard and delayed-contrast MRIs, were studied as possible predictors of outcome. In scans acquired at progression, the average change in lesion volume from previous follow-up in standard and delayed-contrast MRIs was compared.

RESULTS: Response and progression patterns were identified from the mean change in lesion volumes, depicted from conventional T1WI, delayed contrast-enhanced MR imaging, and DSC MR imaging. Thresholds for early prediction of response were calculated by using these sequences. For each predictor, sensitivity, specificity, positive predictive values, and negative predictive values were calculated, reaching 85.7%, 87.5%, 75%, and 93.3% for conventional T1WI; 100%, 87.5%, 77.8%, and 100% for delayed-contrast MR imaging; and 75%, 78.6%, 50%, and 91.7% for DSC MR imaging. The benefit of delayed-contrast MR imaging in separating responders and nonresponders was further confirmed by using log-rank tests (conventional T1WI, P = .0022; delayed-contrast MR imaging, P < .0001; DSC MR imaging, P = .0232) and receiver operating characteristic analyses. At progression, the increase in lesion volumes in delayed-contrast MR imaging was 37.5% higher than the increase in conventional T1WI (P < .01); these findings suggest that progression may be depicted more effectively in treatment-response-assessment maps.

CONCLUSIONS: The benefit of contrast-enhanced MR imaging for assessing and predicting the response to bevacizumab was demonstrated. The increased sensitivity of the treatment-response-assessment maps reflects their potential contribution to the management of bevacizumab-treated patients with recurrent high-grade glioma.

Abbreviations

BlueV
blue volume calculated from the TRAMs
FLAIRV
FLAIR hyperintense volume calculated from precontrast FLAIR MRI
HGG
high-grade glioma
HPV
hyperperfusion volume calculated from DSC MRI
OS
overall survival
PFS
progression-free survival
RANO
Response Assessment in Neuro-Oncology
T1GdV
enhancing volume calculated from contrast-enhanced T1WI
TRAM
treatment-response-assessment map
  • © 2016 American Society of Neuroradiology
Next
Back to top
Advertisement
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas
D. Daniels, D. Guez, D. Last, C. Hoffmann, D. Nass, A. Talianski, G. Tsarfaty, S. Salomon, A.A. Kanner, D.T. Blumenthal, F. Bokstein, S. Harnof, D. Yekutieli, S. Zamir, Z.R. Cohen, L. Zach, Y. Mardor
American Journal of Neuroradiology Jul 2016, DOI: 10.3174/ajnr.A4866

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas
D. Daniels, D. Guez, D. Last, C. Hoffmann, D. Nass, A. Talianski, G. Tsarfaty, S. Salomon, A.A. Kanner, D.T. Blumenthal, F. Bokstein, S. Harnof, D. Yekutieli, S. Zamir, Z.R. Cohen, L. Zach, Y. Mardor
American Journal of Neuroradiology Jul 2016, DOI: 10.3174/ajnr.A4866
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Assessment of Heating on Titanium Alloy Cerebral Aneurysm Clips during 7T MRI
  • Quantitative Collateral Assessment on CTP in the Prediction of Stroke Etiology
  • Survey of the American Society of Neuroradiology Membership on the Use and Value of Intracranial Vessel Wall MRI
Show more ADULT BRAIN

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2021 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2022 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire